Active Ingredient History
Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Dermatology (Phase 2)
Endocrine Gland Neoplasms (Phase 3)
Gastrointestinal Neoplasms (Phase 1/Phase 2)
Hemangiosarcoma (Phase 2)
Intestinal Neoplasms (Phase 1)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 2)
Melanoma (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neuroectodermal Tumors (Phase 3)
Neuroendocrine Tumors (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 1)
Rectal Neoplasms (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 1/Phase 2)
Rhabdomyosarcoma, Alveolar (Phase 1/Phase 2)
Rhabdomyosarcoma, Embryonal (Phase 1/Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 3)
Small Cell Lung Carcinoma (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue